Cargando…
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
BACKGROUND: Several cancer types harbor alterations in the gene encoding AT-Rich Interactive Domain-containing protein 1A (ARID1A), but there are no approved therapies to address these alterations. Recent studies have shown that ARID1A deficiency compromises mismatch repair proteins. Herein, we anal...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057434/ https://www.ncbi.nlm.nih.gov/pubmed/32111729 http://dx.doi.org/10.1136/jitc-2019-000438 |
_version_ | 1783503657663201280 |
---|---|
author | Okamura, Ryosuke Kato, Shumei Lee, Suzanna Jimenez, Rebecca E Sicklick, Jason K Kurzrock, Razelle |
author_facet | Okamura, Ryosuke Kato, Shumei Lee, Suzanna Jimenez, Rebecca E Sicklick, Jason K Kurzrock, Razelle |
author_sort | Okamura, Ryosuke |
collection | PubMed |
description | BACKGROUND: Several cancer types harbor alterations in the gene encoding AT-Rich Interactive Domain-containing protein 1A (ARID1A), but there are no approved therapies to address these alterations. Recent studies have shown that ARID1A deficiency compromises mismatch repair proteins. Herein, we analyzed 3403 patients who had tumor tissue next-generation sequencing. FINDINGS: Among nine cancer subtypes with >5% prevalence of ARID1A alterations, microsatellite instability-high as well as high tumor mutational burden was significantly more frequent in ARID1A-altered versus ARID1A wild-type tumors (20% vs 0.9%, p<0.001; and 26% vs 8.4%, p<0.001, respectively). Median progression-free survival (PFS) after checkpoint blockade immunotherapy was significantly longer in the patients with ARID1A-altered tumors (n=46) than in those with ARID1A wild-type tumors (n=329) (11 months vs 4 months, p=0.006). Also, multivariate analysis showed that ARID1A alterations predicted longer PFS after checkpoint blockade (HR (95% CI), 0.61 (0.39 to 0.94), p=0.02) and this result was independent of microsatellite instability or mutational burden; median overall survival time was also longer in ARID1A-altered versus wild-type tumors (31 months vs 20 months), but did not reach statistical significance (p=0.13). CONCLUSIONS: Our findings suggest that ARID1A alterations merit further exploration as a novel biomarker correlating with better outcomes after checkpoint blockade immunotherapy. |
format | Online Article Text |
id | pubmed-7057434 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-70574342020-03-05 ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy Okamura, Ryosuke Kato, Shumei Lee, Suzanna Jimenez, Rebecca E Sicklick, Jason K Kurzrock, Razelle J Immunother Cancer Short Report BACKGROUND: Several cancer types harbor alterations in the gene encoding AT-Rich Interactive Domain-containing protein 1A (ARID1A), but there are no approved therapies to address these alterations. Recent studies have shown that ARID1A deficiency compromises mismatch repair proteins. Herein, we analyzed 3403 patients who had tumor tissue next-generation sequencing. FINDINGS: Among nine cancer subtypes with >5% prevalence of ARID1A alterations, microsatellite instability-high as well as high tumor mutational burden was significantly more frequent in ARID1A-altered versus ARID1A wild-type tumors (20% vs 0.9%, p<0.001; and 26% vs 8.4%, p<0.001, respectively). Median progression-free survival (PFS) after checkpoint blockade immunotherapy was significantly longer in the patients with ARID1A-altered tumors (n=46) than in those with ARID1A wild-type tumors (n=329) (11 months vs 4 months, p=0.006). Also, multivariate analysis showed that ARID1A alterations predicted longer PFS after checkpoint blockade (HR (95% CI), 0.61 (0.39 to 0.94), p=0.02) and this result was independent of microsatellite instability or mutational burden; median overall survival time was also longer in ARID1A-altered versus wild-type tumors (31 months vs 20 months), but did not reach statistical significance (p=0.13). CONCLUSIONS: Our findings suggest that ARID1A alterations merit further exploration as a novel biomarker correlating with better outcomes after checkpoint blockade immunotherapy. BMJ Publishing Group 2020-02-27 /pmc/articles/PMC7057434/ /pubmed/32111729 http://dx.doi.org/10.1136/jitc-2019-000438 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Short Report Okamura, Ryosuke Kato, Shumei Lee, Suzanna Jimenez, Rebecca E Sicklick, Jason K Kurzrock, Razelle ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy |
title |
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy |
title_full |
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy |
title_fullStr |
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy |
title_full_unstemmed |
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy |
title_short |
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy |
title_sort | arid1a alterations function as a biomarker for longer progression-free survival after anti-pd-1/pd-l1 immunotherapy |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057434/ https://www.ncbi.nlm.nih.gov/pubmed/32111729 http://dx.doi.org/10.1136/jitc-2019-000438 |
work_keys_str_mv | AT okamuraryosuke arid1aalterationsfunctionasabiomarkerforlongerprogressionfreesurvivalafterantipd1pdl1immunotherapy AT katoshumei arid1aalterationsfunctionasabiomarkerforlongerprogressionfreesurvivalafterantipd1pdl1immunotherapy AT leesuzanna arid1aalterationsfunctionasabiomarkerforlongerprogressionfreesurvivalafterantipd1pdl1immunotherapy AT jimenezrebeccae arid1aalterationsfunctionasabiomarkerforlongerprogressionfreesurvivalafterantipd1pdl1immunotherapy AT sicklickjasonk arid1aalterationsfunctionasabiomarkerforlongerprogressionfreesurvivalafterantipd1pdl1immunotherapy AT kurzrockrazelle arid1aalterationsfunctionasabiomarkerforlongerprogressionfreesurvivalafterantipd1pdl1immunotherapy |